NYSE:PMC - PharMerica Stock Price, Price Target & More

$29.25 +0.05 (+0.17 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$29.20
Today's Range$29.20 - $29.27
52-Week Range$22.00 - $29.50
Volume1.37 million shs
Average Volume283,015 shs
Market Capitalization$910.27 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82

About PharMerica (NYSE:PMC)

PharMerica logoPharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. Its segments include institutional pharmacy, which provides pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals and other long-term alternative care settings; specialty infusion services, which provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities, hospice and outside of hospital or nursing home settings, and specialty oncology pharmacy, which provides dispensing of oncology drugs, care management and other related services to patients, oncology practices and hospitals.

Receive PMC News and Ratings via Email

Sign-up to receive the latest news and ratings for PMC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Distributors
SectorN/A
SymbolNYSE:PMC
CUSIP71714F10
Phone+1-502-6277000

Debt

Debt-to-Equity Ratio0.79%
Current Ratio2.58%
Quick Ratio1.79%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio15.23
P/E Growth1.27

Sales & Book Value

Annual Sales$2.09 billion
Price / Sales0.44
Cash Flow$3.8538 per share
Price / Cash7.59
Book Value$17.68 per share
Price / Book1.65

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$21.60 million
Net Margins0.54%
Return on Equity2.30%
Return on Assets1.02%

Miscellaneous

Employees5,700
Outstanding Shares31,120,000

How to Become a New Pot Stock Millionaire

PharMerica (NYSE:PMC) Frequently Asked Questions

What is PharMerica's stock symbol?

PharMerica trades on the New York Stock Exchange (NYSE) under the ticker symbol "PMC."

How were PharMerica's earnings last quarter?

PharMerica Co. (NYSE:PMC) issued its quarterly earnings data on Thursday, November, 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.49 by $0.03. The firm earned $595.10 million during the quarter, compared to the consensus estimate of $596.80 million. PharMerica had a return on equity of 2.30% and a net margin of 0.54%. View PharMerica's Earnings History.

What price target have analysts set for PMC?

4 equities research analysts have issued 1-year price objectives for PharMerica's stock. Their forecasts range from $29.25 to $29.25. On average, they anticipate PharMerica's stock price to reach $29.25 in the next twelve months. View Analyst Ratings for PharMerica.

Who are PharMerica's key executives?

PharMerica's management team includes the folowing people:
  • Geoffrey G. Meyers, Independent Chairman of the Board (Age 72)
  • Gregory S. Weishar, Chief Executive Officer, Director (Age 62)
  • Suresh Vishnubhatla, Executive Vice President - Long-term Care Operations (Age 48)
  • Berard E. Tomassetti, Senior Vice President, Chief Accounting Officer (Age 61)
  • Thomas A. Caneris, Senior Vice President, General Counsel, Secretary (Age 54)
  • Robert A. McKay, Senior Vice President - Purchasing and Trade Relations (Age 55)
  • Frank E. Collins Esq., Independent Director (Age 63)
  • W. Robert Robert Dahl Jr., Independent Director (Age 60)
  • Marjorie W. Dorr, Independent Director (Age 55)
  • Patrick G. LePore, Independent Director (Age 62)

Has PharMerica been receiving favorable news coverage?

Press coverage about PMC stock has been trending somewhat positive on Wednesday, according to Accern. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. PharMerica earned a daily sentiment score of 0.12 on Accern's scale. They also assigned media stories about the company an impact score of 45.29 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of PharMerica?

Shares of PMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PharMerica's stock price today?

One share of PMC stock can currently be purchased for approximately $29.25.

How big of a company is PharMerica?

PharMerica has a market capitalization of $910.27 million and generates $2.09 billion in revenue each year. PharMerica employs 5,700 workers across the globe.

How can I contact PharMerica?

PharMerica's mailing address is 1901 Campus Pl, LOUISVILLE, KY 40299-2308, United States. The company can be reached via phone at +1-502-6277000.


MarketBeat Community Rating for PharMerica (PMC)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  376
MarketBeat's community ratings are surveys of what our community members think about PharMerica and other stocks. Vote "Outperform" if you believe PMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

PharMerica (NYSE:PMC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for PharMerica in the last 12 months. Their average twelve-month price target is $29.25, suggesting that the stock has a possible downside of 0.00%. The high price target for PMC is $29.25 and the low price target for PMC is $29.25. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $29.25$29.25$29.25$29.25
Price Target Upside: 0.00% downside1.04% upside1.04% upside1.04% upside

PharMerica (NYSE:PMC) Consensus Price Target History

Price Target History for PharMerica (NYSE:PMC)

PharMerica (NYSE:PMC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017Barrington ResearchDowngradeOutperform -> UnderperformLowView Rating Details
8/8/2017KeyCorpDowngradeOverweightLowView Rating Details
8/4/2017Credit Suisse GroupDowngradeOutperform -> Neutral$29.00 -> $29.25LowView Rating Details
8/3/2017UBSReiterated RatingNeutral$26.00 -> $29.25LowView Rating Details
6/7/2016Bank of AmericaInitiated CoverageBuy$32.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

PharMerica (NYSE:PMC) Earnings History and Estimates Chart

Earnings by Quarter for PharMerica (NYSE:PMC)

PharMerica (NYSE:PMC) Earnings Estimates

2018 EPS Consensus Estimate: $2.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.46$0.46$0.46
Q2 20181$0.52$0.52$0.52
Q3 20181$0.55$0.55$0.55
Q4 20181$0.59$0.59$0.59

PharMerica (NYSE PMC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017$0.49$0.46$596.80 million$595.10 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.47$0.47$592.96 million$592.00 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.40$0.42$536.85 million$566.80 millionViewN/AView Earnings Details
2/24/2017Q416$0.51$0.58$525.22 million$534.40 millionViewListenView Earnings Details
11/9/2016Q316$0.51$0.44$530.01 million$512.60 millionViewListenView Earnings Details
8/9/2016Q216$0.47$0.47$508.31 million$519.60 millionViewListenView Earnings Details
5/6/2016Q116$0.43$0.45$509.45 million$524.50 millionViewListenView Earnings Details
2/26/2016Q415$0.41$0.45$506.40 million$520.60 millionViewListenView Earnings Details
11/6/2015Q315$0.36$0.39$480.35 million$498.80 millionViewListenView Earnings Details
8/7/2015Q215$0.33$0.37$491.66 million$497.50 millionViewListenView Earnings Details
5/7/2015Q115$0.43$0.48$500.95 million$511.60 millionViewListenView Earnings Details
3/2/2015Q414$0.43$0.45$491.99 million$523.50 millionViewListenView Earnings Details
11/6/2014Q314$0.40$0.45$439.63 million$470.20 millionViewListenView Earnings Details
8/5/2014Q214$0.36$0.40$432.70 million$448.60 millionViewListenView Earnings Details
5/1/2014Q114$0.33$0.37$417.76 million$452.20 millionViewListenView Earnings Details
2/28/2014Q413$0.38$0.44$421.16 million$433.20 millionViewListenView Earnings Details
11/5/2013Q313$0.32$0.49$398.02 million$442.00 millionViewListenView Earnings Details
8/2/2013Q2 2013$0.34$0.44$414.15 million$458.50 millionViewListenView Earnings Details
5/1/2013Q1 2013$0.34$0.46$435.10 million$439.80 millionViewListenView Earnings Details
2/7/2013Q4 2012$0.29$0.12$432.43 million$433.20 millionViewListenView Earnings Details
11/1/2012Q312$0.30$0.33$446.36 million$442.00 millionViewN/AView Earnings Details
8/2/2012$0.30$0.32ViewN/AView Earnings Details
5/2/2012$0.27$0.30ViewN/AView Earnings Details
2/9/2012$0.21$0.27ViewN/AView Earnings Details
11/3/2011$0.20$0.31ViewN/AView Earnings Details
8/4/2011$0.20$0.32ViewN/AView Earnings Details
5/5/2011$0.20$0.21ViewN/AView Earnings Details
2/24/2011$0.17$0.16ViewN/AView Earnings Details
11/4/2010Q3 2010$0.19$0.21ViewN/AView Earnings Details
8/5/2010Q2 2010$0.33$0.22ViewN/AView Earnings Details
5/6/2010Q1 2010$0.34$0.29ViewN/AView Earnings Details
2/4/2010Q4 2009$0.31$0.32ViewN/AView Earnings Details
10/29/2009Q3 2009$0.32$0.35ViewN/AView Earnings Details
8/3/2009Q2 2009$0.28$0.31ViewN/AView Earnings Details
4/30/2009Q1 2009$0.25$0.31ViewN/AView Earnings Details
2/5/2009Q4 2008$0.21$0.26ViewN/AView Earnings Details
10/30/2008Q3 2008$0.20$0.27ViewN/AView Earnings Details
8/7/2008Q2 2008$0.17$0.22ViewN/AView Earnings Details
5/8/2008Q1 2008$0.13$0.20ViewN/AView Earnings Details
2/18/2008Q4 2007$0.08$0.21ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

PharMerica (NYSE:PMC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

PharMerica (NYSE PMC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.04%
Institutional Ownership Percentage: 89.97%
Insider Trading History for PharMerica (NYSE:PMC)
Institutional Ownership by Quarter for PharMerica (NYSE:PMC)

PharMerica (NYSE PMC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/7/2017Gregory S. WeisharCEOSell521,089$29.25$15,241,853.25View SEC Filing  
11/2/2017Paul Valerian TeodoroviciDirectorSell8,000$0.09$720.00
10/5/2017Edward Leith EllwoodInsiderSell3,000$0.10$300.00
10/3/2017Edward Leith EllwoodInsiderSell2,000$0.10$200.00
8/17/2017Edward Leith EllwoodInsiderSell20,000$0.09$1,800.00
7/27/2017Edward Leith EllwoodInsiderSell3,000$0.08$240.00
7/25/2017Edward Leith EllwoodInsiderSell1,000$0.08$80.00
3/31/2017Edward Leith EllwoodInsiderSell35,000$0.07$2,450.00
12/2/2015Robert A MckaySVPSell2,993$34.42$103,019.0670,806View SEC Filing  
11/11/2015Mark LindemoenSVPSell3,790$34.71$131,550.9018,009View SEC Filing  
6/16/2015Robert A MckaySVPSell7,000$32.75$229,250.00View SEC Filing  
6/3/2015Gregory S WeisharCEOSell104,150$32.63$3,398,414.50View SEC Filing  
6/1/2015Mark LindemoenSVPSell4,500$33.27$149,715.00View SEC Filing  
3/12/2015Berard TomassettiCAOSell3,344$26.44$88,415.36View SEC Filing  
3/12/2015Thomas A CanerisSVPSell7,495$26.52$198,767.40View SEC Filing  
3/6/2015Robert A MckaySVPSell20,000$26.74$534,800.00View SEC Filing  
8/8/2014Robert A OakleyDirectorSell8,399$26.55$222,993.45View SEC Filing  
5/13/2014Thomas CanerisSVPSell12,192$28.60$348,691.2075,702View SEC Filing  
3/14/2014Gregory WeisharCEOSell60,000$26.27$1,576,200.00711,001View SEC Filing  
3/13/2014Robert MckaySVPSell18,646$26.08$486,287.6876,936View SEC Filing  
3/12/2014Berard TomassettiCAOSell3,812$25.22$96,138.649,595View SEC Filing  
3/6/2014Thomas CanerisSVPSell14,357$25.60$367,539.2057,126View SEC Filing  
11/22/2013Thomas GerrityDirectorSell3,271$20.56$67,251.7640,115View SEC Filing  
11/15/2013Berard TomassettiCAOSell4,097$20.55$84,193.3510,263View SEC Filing  
5/30/2013Berard TomassettiCAOSell9,724$15.68$152,472.32View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

PharMerica (NYSE PMC) News Headlines

Source:
DateHeadline
Zacks Investment Research Downgrades PharMerica (PMC) to HoldZacks Investment Research Downgrades PharMerica (PMC) to Hold
www.americanbankingnews.com - April 17 at 8:43 PM
PharMerica (PMC) Stock Rating Lowered by BidaskClubPharMerica (PMC) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 9:51 PM
PharMerica (PMC) Lowered to "Overweight" at KeyCorpPharMerica (PMC) Lowered to "Overweight" at KeyCorp
www.americanbankingnews.com - April 14 at 10:17 AM
Barrington Research Lowers PharMerica (PMC) to UnderperformBarrington Research Lowers PharMerica (PMC) to Underperform
www.americanbankingnews.com - April 13 at 7:49 PM
PharMerica (PMC) Lowered to "Underperform" at Barrington ResearchPharMerica (PMC) Lowered to "Underperform" at Barrington Research
www.americanbankingnews.com - April 12 at 3:58 PM
ValuEngine Upgrades PharMerica (PMC) to "Buy"ValuEngine Upgrades PharMerica (PMC) to "Buy"
www.americanbankingnews.com - April 3 at 10:58 PM
PharMerica (PMC) Scheduled to Post Quarterly Earnings on ThursdayPharMerica (PMC) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - February 15 at 2:02 AM
PharMerica Co. (PMC) Given Average Recommendation of "Hold" by BrokeragesPharMerica Co. (PMC) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 25 at 1:30 AM
PharMerica Co. (PMC) Given Average Rating of "Hold" by BrokeragesPharMerica Co. (PMC) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 31 at 1:58 AM
Walgreens Closes PharMerica Buyout as KKRs Minority PartnerWalgreens Closes PharMerica Buyout as KKR's Minority Partner
www.msn.com - December 18 at 10:38 AM
Pharmerica Corp (PMC) CEO Gregory S Weishar Sold $15.2 million of SharesPharmerica Corp (PMC) CEO Gregory S Weishar Sold $15.2 million of Shares
finance.yahoo.com - December 11 at 4:51 PM
PharMerica Co. (PMC) CEO Sells $15,241,853.25 in StockPharMerica Co. (PMC) CEO Sells $15,241,853.25 in Stock
www.americanbankingnews.com - December 11 at 2:22 PM
Zacks: Brokerages Expect PharMerica Co. (PMC) Will Post Quarterly Sales of $614.00 MillionZacks: Brokerages Expect PharMerica Co. (PMC) Will Post Quarterly Sales of $614.00 Million
www.americanbankingnews.com - December 8 at 12:06 PM
PharMerica Co. (PMC) Given Consensus Rating of "Hold" by BrokeragesPharMerica Co. (PMC) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 6 at 1:46 AM
$614.00 Million in Sales Expected for Pharmerica Corporation (PMC) This Quarter$614.00 Million in Sales Expected for Pharmerica Corporation (PMC) This Quarter
www.americanbankingnews.com - November 20 at 6:28 AM
Zacks: Analysts Expect Pharmerica Corporation (PMC) Will Post Earnings of $0.52 Per ShareZacks: Analysts Expect Pharmerica Corporation (PMC) Will Post Earnings of $0.52 Per Share
www.americanbankingnews.com - November 18 at 3:30 PM
PharMerica Corp. breached its 50 day moving average in a Bullish Manner : PMC-US : November 17, 2017PharMerica Corp. breached its 50 day moving average in a Bullish Manner : PMC-US : November 17, 2017
finance.yahoo.com - November 18 at 10:59 AM
Zacks: Brokerages Expect Pharmerica Corporation (PMC) Will Post Quarterly Sales of $614.00 MillionZacks: Brokerages Expect Pharmerica Corporation (PMC) Will Post Quarterly Sales of $614.00 Million
www.americanbankingnews.com - November 15 at 11:08 AM
PharMerica shareholders vote on $1.4 billion acquisitionPharMerica shareholders vote on $1.4 billion acquisition
finance.yahoo.com - November 12 at 11:44 AM
PharMerica Reports Third Quarter 2017 ResultsPharMerica Reports Third Quarter 2017 Results
finance.yahoo.com - November 12 at 11:44 AM
PharMerica posts 3Q profitPharMerica posts 3Q profit
finance.yahoo.com - November 12 at 11:44 AM
Why PharMerica Corporation (PMC) Delivered An Inferior ROE Compared To The IndustryWhy PharMerica Corporation (PMC) Delivered An Inferior ROE Compared To The Industry
finance.yahoo.com - November 12 at 11:44 AM
Pharmerica Corporation (PMC) Receives Average Rating of "Hold" from AnalystsPharmerica Corporation (PMC) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 11 at 1:46 AM
Pharmerica Corporation (PMC) Announces Quarterly  Earnings ResultsPharmerica Corporation (PMC) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 3:36 PM
PharMerica misses by $0.06, misses on revenuePharMerica misses by $0.06, misses on revenue
seekingalpha.com - November 9 at 3:38 PM
PharMerica Corp. breached its 50 day moving average in a Bullish Manner : PMC-US : November 7, 2017PharMerica Corp. breached its 50 day moving average in a Bullish Manner : PMC-US : November 7, 2017
finance.yahoo.com - November 7 at 8:50 AM
PharMerica Corp. – Value Analysis (NYSE:PMC) : October 30, 2017PharMerica Corp. – Value Analysis (NYSE:PMC) : October 30, 2017
finance.yahoo.com - October 31 at 8:00 AM
Pharmerica Corporation (PMC) Scheduled to Post Earnings on TuesdayPharmerica Corporation (PMC) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 31 at 2:50 AM
ETFs with exposure to PharMerica Corp. : October 26, 2017ETFs with exposure to PharMerica Corp. : October 26, 2017
finance.yahoo.com - October 27 at 10:46 AM
PharMerica Corp. breached its 50 day moving average in a Bearish Manner : PMC-US : October 27, 2017PharMerica Corp. breached its 50 day moving average in a Bearish Manner : PMC-US : October 27, 2017
finance.yahoo.com - October 27 at 10:46 AM
Onco360 Selected for VERZENIO® Limited Distribution Pharmacy NetworkOnco360 Selected for VERZENIO® Limited Distribution Pharmacy Network
finance.yahoo.com - October 17 at 6:20 AM
Pharmerica Corporation (PMC) Receives Consensus Recommendation of "Hold" from AnalystsPharmerica Corporation (PMC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 17 at 2:52 AM
PharMerica details millions in golden parachute money for executivesPharMerica details millions in golden parachute money for executives
finance.yahoo.com - October 7 at 7:26 AM
BEHIND THE DEAL: PharMerica reveals how its $1.4 billion acquisition came togetherBEHIND THE DEAL: PharMerica reveals how its $1.4 billion acquisition came together
www.bizjournals.com - October 5 at 9:52 PM
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against PharMerica CorporationFaruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against PharMerica Corporation
finance.yahoo.com - October 5 at 4:49 PM
PharMerica Corp. :PMC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017PharMerica Corp. :PMC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 3 at 10:52 AM
Pharmerica Corporation (PMC) Short Interest UpdatePharmerica Corporation (PMC) Short Interest Update
www.americanbankingnews.com - October 3 at 3:32 AM
Pharmerica Corporation (PMC) Expected to Post Quarterly Sales of $596.80 MillionPharmerica Corporation (PMC) Expected to Post Quarterly Sales of $596.80 Million
www.americanbankingnews.com - September 23 at 9:28 AM
Pharmerica Corporation (PMC) Given Average Rating of "Hold" by BrokeragesPharmerica Corporation (PMC) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 22 at 2:34 AM
PharMerica Corporation -- Moodys assigns B2 CFR to PharMerica Corporation; outlook stablePharMerica Corporation -- Moody's assigns B2 CFR to PharMerica Corporation; outlook stable
finance.yahoo.com - September 13 at 7:54 AM
$596.80 Million in Sales Expected for Pharmerica Corporation (PMC) This Quarter$596.80 Million in Sales Expected for Pharmerica Corporation (PMC) This Quarter
www.americanbankingnews.com - September 4 at 4:52 AM
Pharmerica Corporation (PMC) Sees Significant Growth in Short InterestPharmerica Corporation (PMC) Sees Significant Growth in Short Interest
www.americanbankingnews.com - August 31 at 1:46 AM
Pharmerica Corporation (PMC) Given Average Recommendation of "Hold" by BrokeragesPharmerica Corporation (PMC) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 28 at 2:36 AM
Comparing Pharmerica Corporation (PMC) and MWI Veterinary Supply (MWIV)Comparing Pharmerica Corporation (PMC) and MWI Veterinary Supply (MWIV)
www.americanbankingnews.com - August 22 at 8:30 AM
Analyzing Pharmerica Corporation (PMC) & MWI Veterinary Supply (MWIV)Analyzing Pharmerica Corporation (PMC) & MWI Veterinary Supply (MWIV)
www.americanbankingnews.com - August 20 at 4:22 AM
MWI Veterinary Supply (MWIV) and Pharmerica Corporation (PMC) Financial ReviewMWI Veterinary Supply (MWIV) and Pharmerica Corporation (PMC) Financial Review
www.americanbankingnews.com - August 14 at 12:28 AM
Head to Head Review: Pharmerica Corporation (NYSE:PMC) & Cardinal Health (CAH)Head to Head Review: Pharmerica Corporation (NYSE:PMC) & Cardinal Health (CAH)
www.americanbankingnews.com - August 10 at 10:24 PM
Pharmerica Corporation (NYSE:PMC) Lowered to "Overweight" at KeyCorpPharmerica Corporation (NYSE:PMC) Lowered to "Overweight" at KeyCorp
www.americanbankingnews.com - August 8 at 8:56 PM
Research Analysts Offer Predictions for Pharmerica Corporations Q4 2018 Earnings (PMC)Research Analysts Offer Predictions for Pharmerica Corporation's Q4 2018 Earnings (PMC)
www.americanbankingnews.com - August 7 at 9:30 AM
Pharmerica Corporation (PMC) Cut to "Neutral" at Credit Suisse GroupPharmerica Corporation (PMC) Cut to "Neutral" at Credit Suisse Group
www.americanbankingnews.com - August 6 at 9:40 PM

SEC Filings

PharMerica (NYSE:PMC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

PharMerica (NYSE:PMC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

PharMerica (NYSE PMC) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.